Ryan Troup

Ryan Troup is the Editor in Chief of Wealthy VC. Ryan has 15+ years of investing experience. X | Email
Consumer

ELEVAI Skincare CEO to Present at Beauty Through Science Conference in Stockholm, Sweden

ELEVAI Labs (NASDAQ: ELAB), a pioneering force in medical aesthetics, announced that Chief Executive Officer Jordan R. Plews, PhD has…

Read More »
Politics

Trump Embraces Crypto Donations: A Potential Game Changer for Political Fundraising

In a groundbreaking move, Donald J. Trump’s 2024 presidential campaign has announced it will accept cryptocurrency donations, marking the first…

Read More »
Crypto

Ethereum ETFs Approved: A New Era for Cryptocurrency Investment

The recent approval by the U.S. Securities and Exchange Commission (SEC) of spot Ethereum (ETHUSD) exchange-traded funds (ETFs) marks a…

Read More »
Biotech

ELEVAI Biosciences CEO to Showcase Company’s Obesity and Muscle Loss Prevention Technology at UCLA LA-BEST 2024 Conference

ELEVAI Labs (NASDAQ: ELAB), a pioneering force in medical aesthetics, announced that Chief Executive Officer Dr. Jordan R. Plews, PhD…

Read More »
Biotech

ELEVAI Labs Reports Q1 Earnings — Revenue Grows 330%

ELEVAI Labs (NASDAQ: ELAB), a pioneering force in medical aesthetics, reported its financial results for the first quarter ended March…

Read More »
Featured

ELEVAI Labs: A Strategic Expansion in Biosciences and Skincare

ELEVAI Labs (NASDAQ: ELAB), a pioneering force in medical aesthetics, has made significant strides of late with the launch of…

Read More »
Biotech

ELEVAI Labs Announces Launch of ELEVAI Biosciences and ELEVAI Skincare Subsidiaries

ELEVAI Labs established two subsidiaries: ELEVAI Biosciences, Inc., and ELEVAI Skincare, Inc. ELEVAI Biosciences will focus on acquiring and developing…

Read More »
Biotech

ELEVAI Labs Acquires Exclusive License to Develop and Commercialize Novel Assets to Treat Obesity and Muscle Loss Prevention

The agreement adds two drug candidates to the company’s product pipeline, “EL-22”, a clinical-stage engineered probiotic expressing myostatin, and “EL-32”,…

Read More »
Biotech

ELEVAI Labs Releases Global Distribution Partnership Overview Featuring $4.9 Million in Potential Top Line Revenue Commitments

The company’s international distribution agreements have a contracted cumulative minimum purchase requirement of up to $4.9 million over the first…

Read More »
Biotech

ELEVAI Labs Signs International Distribution Agreement to Enter Taiwan Market

The Asia-Pacific market represents a $13 billion prestige skincare and luxury haircare market opportunity, with the Taiwan deal giving the…

Read More »
Back to top button
🔔
Stay Updated!
Get notifications for new content